Emodin attenuates silica-induced lung injury by inhibition of inflammation, apoptosis and epithelial-mesenchymal transition

Xinru Pang,Linlin Shao,Xiaojuan Nie,Haiyue Yan,Chao Li,Abrey J Yeo,Martin F Lavin,Qing Xia,Hua Shao,Gongchang Yu,Qiang Jia,Cheng Peng,Abrey J. Yeo,Martin F. Lavin
DOI: https://doi.org/10.1016/j.intimp.2020.107277
IF: 5.714
2021-02-01
International Immunopharmacology
Abstract:<p>Silicosis is a fatal pulmonary disease caused by the inhalation of silica dust, and characterized by inflammation and fibrosis of the lung, with no effective treatment to date. Here we investigate the effect of emodin, an anthraquinone derivative isolated from rhubarb using a mouse silicosis model and in vitro cultured human macrophages and alveolar epithelial cells. Results from histological examination indicated that emodin reduced the degree of alveolitis and fibrosis in the lungs of mice exposed to silica particles. We also demonstrated that emodin effectively inhibited the phosphorylation of Smad3 and NF-κB and reduced the levels of inflammatory factors in the lung tissue of mice treated with silica particles. In addition, we found that emodin inhibited apoptosis and demonstrated an anti-fibrotic effect by down-regulating the pro-apoptotic protein Bax and up-regulating the anti-apoptotic protein Bcl-2. Furthermore, emodin increased E-cadherin levels, reduced the expression of Vimentin, α-SMA and Col-I, as well as pro-inflammatory factors TGF-β1, TNF-α and IL-1β in vivo and in vitro. These results suggested that emodin can regulate epithelial–mesenchymal transition (EMT) through the inhibition of the TGF-β1/Smad3 signaling pathway and the NF-κB signaling pathway to prevent alveolar inflammation and apoptotic process. Overall, this study showed that emodin can alleviate pulmonary fibrosis in silicosis through regulating the inflammatory response and fibrotic process at multiple levels.</p>
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the treatment dilemma of silicosis. Silicosis is a fatal lung disease caused by inhalation of free silica particles, characterized by lung inflammation and fibrosis, and there is currently no effective treatment method. In this paper, by studying the effect of emodin on the mouse silicosis model, it is explored whether emodin can reduce lung damage caused by silicosis by inhibiting inflammation, apoptosis and epithelial - mesenchymal transition (EMT). Specifically, the researchers used the mouse silicosis model and human macrophages and alveolar epithelial cells cultured in vitro to evaluate the effects of emodin in the following aspects: 1. **Reducing lung inflammation**: Through histological examination, it was found that emodin can reduce the degree of inflammation in the mouse lungs. 2. **Inhibiting the phosphorylation of Smad3 and NF - κB**: Emodin can effectively inhibit the phosphorylation of Smad3 and NF - κB, thereby reducing the levels of inflammatory factors in lung tissues. 3. **Inhibiting apoptosis**: Emodin shows anti - apoptotic effects by down - regulating the pro - apoptotic protein Bax and up - regulating the anti - apoptotic protein Bcl - 2. 4. **Regulating the EMT process**: Emodin increases the expression of E - cadherin, reduces the expressions of Vimentin, α - SMA and Col - I, as well as the levels of pro - inflammatory factors TGF - β1, TNF - α and IL - 1β, thus showing anti - fibrotic effects in both in vivo and in vitro experiments. These results indicate that emodin can relieve pulmonary fibrosis caused by silicosis at multiple levels by regulating the inflammatory response and the fibrotic process. Overall, this study provides new ideas and potential therapeutic drugs for the prevention and treatment of silicosis.